Prof Umberto Vitolo speaks to ecancer about the phase 3 frontMIND trial.

This trial evaluated the addition of tafasitamab and lenalidomide to standard R-CHOP in patients with previously untreated high-risk diffuse large B-cell lymphoma and high-grade B-cell lymphoma.

The combination significantly improved progression-free survival, reducing the risk of disease progression or death by 25% compared to R-CHOP alone, with higher 24-month PFS rates observed across molecular subtypes and risk groups.

Event-free survival was also improved, while overall response rates and complete response rates remained similar between treatment arms.

Safety was manageable, with higher rates of grade 3 or higher adverse events in the combination arm but similar treatment discontinuation rates and fewer overall deaths.

These results support tafasitamab plus lenalidomide with R-CHOP as a potential new first-line standard of care for patients with high-risk DLBCL, offering improved disease control without compromising quality of life.